Adverse Drug Reaction (ADR)
Conditions
Keywords
Pharmacogenomics, Pediatrics, Adverse Drug Reactions
Brief summary
This project addresses the problem of adverse drug reactions in the three most frequently prescribed therapeutic classes of drugs in children: antibiotics, analgesics, and mental health medications. We will conduct pilot testing of a pharmacogenomic testing panel and study how the tests and generated test results are utilized and understood by physicians, pharmacists, patients and their families.
Detailed description
The specific objectives are to: 1. Implement a pilot pharmacogenomics program to test medication safety and effectiveness of antibiotics, analgesics and mental health medication to enhance prescribing decision-making. 2. Develop data collection forms to collect necessary patient information from the prescribing physicians. 3. Develop pharmacogenomics reports to return results to physicians, pharmacists, patients and their families. 4. Determine how the tests and results are perceived and utilized by physicians, pharmacists, patients and their families.
Interventions
None listed
Sponsors
University of British Columbia
Genome British Columbia
Genome Canada
Dynacare Laboratories, Inc.
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Participants will be enrolled if they can benefit from pharmacogenomic testing. This means their physician is considering the use of a drug that is part of the panels (analgesics, antibiotics, and mental health medication) or they are already using one.
Exclusion criteria
* Patients who do not speak or understand English.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 150 participants on analgesics, anti-infectives and psychotropics will be given pharmacogenomic recommendations for the risk of gene related adverse events prior to or during treatment. | June 2020 | We will be able to determine the barriers and facilitators of the implementation of the pharmacogenomic service in a health care facility. This will be done by using standardized questionnaires after each pharmacogenomic report is issued. The prescriber and the patient will both answer questions about the utility of the genetic results, the format of the report and the clarity of the content. Results will be recorded and summarized every 25 patients in order to improve the service and the recommendations through the study. |
Countries
Canada
Contacts
CONTACTBruce Carleton, PharmD.
Outcome results
None listed